www.sciencedirect.com/science/article/abs/pii/S1556086419305994
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but
Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-gen…
www.sciencedirect.com
pubmed.ncbi.nlm.nih.gov/31377341/
EGFR-Mutated Lung Cancers Resistant to Osimertinib Through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but
EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. In this clinical scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanism
pubmed.ncbi.nlm.nih.gov
Conclusion
EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. In this clinical scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance—in clinical specimens and preclinical systems—indicate that EGFR C797S along with EGFR T790M can evolve. This report adds to the growing understanding of tumor evolution or adaptability to sequential EGFR inhibition and augments support for exploring combination therapies to delay or prevent on-target resistance.
타그리소 내성이 올 경우 임시적으로 이레사나 타세바를 사용해도 효과가 있다는 뜻?